WO2011050826A1 - Process for making crystalline form a of linezolid - Google Patents

Process for making crystalline form a of linezolid Download PDF

Info

Publication number
WO2011050826A1
WO2011050826A1 PCT/EP2009/007919 EP2009007919W WO2011050826A1 WO 2011050826 A1 WO2011050826 A1 WO 2011050826A1 EP 2009007919 W EP2009007919 W EP 2009007919W WO 2011050826 A1 WO2011050826 A1 WO 2011050826A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
linezolid
process according
antisolvent
solution
form
Prior art date
Application number
PCT/EP2009/007919
Other languages
French (fr)
Inventor
Raymond Jozef Hubertus Westheim
Original Assignee
Synthon B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2

Abstract

The invention relates to a process for making a crystalline linezolid, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a pre-selected temperature and seeded with crystals of the desired crystalline form of linezolid,

Description

PROCESS FOR MAKING CRYSTALLINE FORM A OF LINEZOLID

BACKGROUND OF THE INVENTION

The present invention relates to an improved process for making the compound linezolid, especially in its specific crystalline form called Form A.

Linezolid is a pharmaceutically active compound useful as an antibacterial agent, e.g. for the treatment of diabetic food infections caused by Gram-positive bacteria. It is represented by the formula (I).

Figure imgf000002_0001

The marketed pharmaceutical compositions are a sterile isotonic solution for an i.v. infusion, a tablet for oral administration and an aqueous suspension for oral administration. They are marketed, i.e., under brand name ZYVOX by Pfizer. The molecule of linezolid has one asymmetric carbon in the molecule allowing for 2 enantiomers; the marketed compound is the (S)-enantiomer. In the above-marketed compositions, linezolid is present as a free base.

Hereinunder, the name linezolid will be used as the generic name for N-(3-(3-fluoro-4- (mo holin-4- l)phen l)-2-oxooxazolidin-5(S)-ylmethyl)acetamide, unless indicated to the contrary.

Linezolid was first disclosed in WO 95/07271 (EP 0717738, US 5,688,792) of the

Upjohn Company. Various solid state forms of linezolid have been disclosed in the prior art: crystalline Form I (J.Med.Chem. 39(3), 673 (1996)), Form II (WO 01/057035, US 6,559,305), Form III (WO 2005/035530) and many others (WO 2006/004922 , US 2006/0142283), amorphous form (WO 2007/026369) and hydrated forms (US 2006/01 1350, EP 2033960).

Among the solid state forms of linezolid, the crystalline Form III of WO 2005/035530 is of certain importance in pharmaceutical industry as it is a sufficiently stable, good crystalline form with a good processability and compatibility with pharmaceutical excipients, particularly for making solid state dosage forms.

The Form III was obtained in the original WO2005/035530, e.g., by heating linezolid at 130-140°C, refluxing in a solvent such as toluene or xylene or by crystallization from a seeded solution in a solvent.

The WO 2009/063505 obtained the crystalline linezolid ( which corresponds to the Form III by evaluating of the disclosed XRPD pattern) by crystallization from various polar aprotic organic solvents, preferably from dioxane/di-isopropyl ether mixture, or by a rapid

crystallization from an ester solvent.

As many crystalline forms of linezolid have been disclosed in the literature, there is a risk of misinterpretation of data from different sources. For instance, the Form III of

WO2005/035530 appeared to be identical with the product of WO 95/07271 (Form I) during prosecution. For reasons of clarity the solid state form of linezolid resulting from the processes described in the present application is denoted Form A throughout the specification and is defined by its X-ray powder diffraction (XRPD) data. In respect to the prior art, it can either correspond to previously denoted Form I or to Form III. While several production processes of making the crystalline linezolid are known in the art, an improvement in this respect is still desirable.

SUMMARY OF THE INVENTION

The present invention relates to the discovery of a new process for making the crystalline linezolid, in particular the Form A of linezolid, as defined hereinafter, which process is useful in a reliable production on an industrial scale. The process is characterized by a rapid and controlled precipitation of the solid linezolid from a solution thereof in an organic solvent by means of an antisolvent.

According to a first aspect of the present invention, there is provided a process for crystallizing linezolid, especially in the crystalline Form A, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a pre-selected temperature and seeded with crystals of the desired crystalline form of linezolid, especially linezolid Form A.

According to particular aspect, the formed linezolid Form A is substantially free from other solid state forms of linezolid, particularly from the Form II and/or from hydrated forms.

According to another particular aspect, the organic solvent is selected from an aliphatic alcohol, a cyclic ether or an aliphatic ester and mixtures thereof. Advantageously, the organic solvents are essentially anhydrous.

According to yet another particular aspect, the antisolvent is a] an aliphatic hydrocarbon, which preferably is a hexane such as n-hexane, a heptane such as n-heptane, a cyclohexane and/or petroleum ether; b] an aliphatic ether , which preferably is methyl-tert.butyl ether ; and mixtures thereof. Advantageously, the temperature of the solution is within the range from 50 °C up to the reflux temperature.

Yet advantageously, the pre-selected temperature of the antisolvent is within the range from -20°C to +25°C, preferably at a temperature lower than 0°C.

Detailed description of the invention

The known processes of making the crystalline linezolid by a "classical" crystallization, i.e. the processes characterized by providing a solution of linezolid at an enhanced temperature and cooling the solution until a crystalline solid starts to precipitate therefrom, have the principal disadvantage in that these processes are hardly controllable, particularly in the large scale production. Dependent on the nature of the solvent, the concentration of the linezolid therein, the chemical purity of the compound, the speed of cooling and intensity of stirring, the crystals can precipitate from the supersaturated solution at different temperatures and with different speed, which can lead to undesirably low batch/to/batch uniformity in the shape and size of crystals. What is even more important, undesired crystalline forms of linezolid may be formed by crystallization instead of the desired form .

The process of the present invention, based on a technique in which a hot solution of linezolid in a solvent is brought into a contact with an anti-solvent ( i.e. with a liquid in which the linezolid is practically insoluble) at a defined, pre-determined temperature with a defined, pre-determined speed, and in the presence of seeds of the desired crystalline form of linezolid , allows to form crystals of linezolid under reliable and well controllable conditions, which are particularly important in a large scale production. The process of the present invention is particularly useful for making the crystalline Form A of linezolid and, therefore, it is discussed hereinunder in details in respect to this form. It is not meant, however, that the invention is limited to processes of making the Form A only.

Throughout the disclosure and claims, the "Form A" of linezolid is a crystalline form of linezolid that is characterized by a XRPD powder diffraction pattern comprising , inter alia, the peaks at about 7.6, 9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9 and 29.9 degrees 2 theta ( ± 0.2 degrees 2 theta) . Such pattern may be obtained when measured with CuKal radiation (λ = 1.54060 A). The XRPD pattern of the Form A obtained by the process of the present invention substantially corresponds to that as disclosed for the Form III in WO

2005/035530. "Substantially corresponds" is meant to cover variations/differences in the pattern that would not be understood by a worker skilled in the art to represent a difference in crystal structure, but rather differences in technique, sample preparation, impurities, etc.

The Form A of linezolid produced by the process of the present invention has an excellent batch-to-batch uniformity in the size and shape of the formed crystals. Importantly, the process provides for crystals of a relatively small average size, which is advantageous and very suitable property for formulation into pharmaceutical compositions. According to one particular aspect of the invention, the linezolid Form A crystals produced by the process of the present invention are advantageously substantially free from other crystalline forms of linezolid, particularly from the Form II of linezolid, which can be otherwise very easily formed by any process of "classical crystallization". In this respect, the "substantially free" means that less than 10%, and advantageously less than 5% of other crystalline forms are present in the precipitated and/or isolated product comprising the Form A of linezolid. In the first step of the process of the present invention, a solution of linezolid in a suitable solvent is provided.

The linezolid starting material useful for making the solution can be in any physical form of linezolid base including the hydrated forms, in any degree of purity. The starting linezolid can also be crude linezolid that is present in the reaction mixtures obtained after the chemical synthesis of linezolid (an example is, e.g., WO 95/07271) or after liberation of linezolid base from a linezolid salt. Processes for obtaining linezolid and its isolated forms are well known in the art.

Typically, the solvent is an organic solvent. According to an important aspect, the solvent is essentially anhydrous, i.e. it does not comprise water or may comprise only traces of water . This is because of a risk of forming linezolid hydrates, which should be limited or avoided. The organic solvent is advantageously a polar organic solvent, more advantageously that of having less than 10 carbon atoms; suitable examples comprise, alone or in an admixture: an aliphatic ester, e.g. ethyl acetate, an aliphatic alcohol, e.g. methanol , ethanol or isopropanol, a cyclic ether, e.g. 1,4-dioxane.

The solution is provided by dissolving linezolid in the solvent preferably at an enhanced temperature. The enhanced temperature comprises any temperature within the range from 50 °C up to the reflux temperature. The suitable concentration of linezolid in the solvent is so selected that the solution can be kept at the chosen temperature without any danger of nucleation at said temperature. In an example, the concentration comprises a range of between 10- 100 ml of the solvent per 1 gram of linezolid. Whenever necessary or appropriate, the solution may be filtered hot to remove undesired solid particles, optionally in the presence of a surface active material, e.g. activated carbon, for to improve colour and clarity of the solution.

In the second step, the obtained solution is contacted with the antisolvent, which is kept cold at a pre-selected temperature.

The useful antisolvent is a liquid, in which the linezolid is essentially insoluble.

Advantageously, the antisolvent comprises an aliphatic and/or alicyclic hydrocarbon , preferably the hydrocarbon with 5 to 10 carbon atoms, or an aliphatic ether, preferably that of 4 to 10 carbon atoms. In an example, the antisolvent is a hexane such as n-hexane, a heptane such as n- heptane, a cyclohexane, methyl-tert. -butyl ether and/or petroleum ether, and mixtures thereof. Preferably, the antisolvent is free from the traces of water.

Prior to any addition of the linezolid solution, the antisolvent is temperated and kept cold at a predetermined temperature below +25° C under stirring. Typically, the temperature of the antisolvent is within the range between -20°C to +25°C, preferably between -15 and 0°C.

Typically, the mutual ratio between the antisolvent and the solvent is from 1 : 1 to 10 : 1

(v/v), advantageously from 2 : 1 to 7 : 1 (v/v) .

Immediately before contacting the linezolid solution with the antisolvent, the antisolvent is seeded with seeds of the desired Form A of linezolid. These seeds may be obtained by heating linazolid (produced following US 5,688, 792) at 130°C to 140°C under nitrogen atmosphere for 4 hours). This is important as no spontaneous nucleation is allowed. Typically, the relative amount of the seeds in respect to the weight of the linezolid in the solution is 1- 25 %. Seeds of other crystalline forms of linezoid, such as seeds of linezoid Form I and Form III may be obtained using processes known in the art. The rate of the addition of the solution into the antisolvent is not specifically limited and is advantageously so selected that the whole volume of the solution is poured into the stirred antisolvent in 30 minutes or less. Care is to be taken that the cooling speed is sufficient to maintain the temperature of the formed mixture at the predetermined value. Advantageously, the actual temperature during the period of contacting the solution with the antisolvent does not exceed + 5°C from the predetermined temperature. Care is also to be taken that the nucleation does not start prior to the contact of the solution with the antisolvent. Thus, the pipelines and valves coming into the contact with the hot solution should be advantageously pre-heated to a suitable temperature.

It should be noted that the order of contacting the solution with the antisolvent cannot be reversed, i.e. the antisolvent may not be added to the hot solution. In such reversed process, the linezolid rather precipitates as the Form II.

By controlled addition of the above linezolid solution into the stirred and seeded antisolvent, the precipitate is formed practically immediately after contacting of both fluids. The precipitate comprises small and uniform particles of the Form A of linezolid. If the above process conditions are met, the precipitate comprises the product, which is essentially free from the Form II of linezolid and/or from any hydrated form thereof.

The precipitated product can be isolated from the mixture by conventional techniques, e.g. filtering or centrifugation, and can be washed, preferably by a fresh antisolvent, and dried.

The linezolid Form A prepared by the process of the present invention can be formulated and used in pharmaceutical compositions. For instance, a suitable pharmaceutical composition may comprise the linezolid Form A and at least one pharmaceutically acceptable excipient. Pharmaceutically acceptable excipients are known in the art and include carriers, diluents, fillers, binders, lubricants, disintegrants, glidants, colorants, pigments, taste masking agents, sweeteners, flavorants, plasticizers, and any acceptable auxiliary substances such as absorption enhancers, penetration enhancers, surfactants, co-surfactants, and specialized oils. The proper excipient(s) are selected based in part on the dosage form, the intended mode of administration, the intended release rate, and manufacturing reliability. Examples of common types of excipients include various polymers, waxes, calcium phosphates, sugars, etc. Polymers include cellulose and cellulose derivatives such as HPMC, hydroxypropyl cellulose, hydroxyethyl cellulose, microcrystalline cellulose, carboxymethylcellulose, sodium carboxymethylcellulose, calcium carboxymethylcellulose, and ethylcellulose; polyvinylpyrrolidones; polyethylenoxides;

polyalkylene glycols such as polyethylene glycol and polypropylene glycol; and polyacrylic acids including their copolymers and crosslinked polymers thereof, e.g., Carbopol® (B.F.

Goodrich), Eudragit® (Rohm), polycarbophil, and chitosan polymers. Waxes include white beeswax, microcrystalline wax, carnauba wax, hydrogenated castor oil, glyceryl behenate, glycerylpalmito stearate, and saturated polyglycolyzed glycerate. Calcium phosphates include dibasic calcium phosphate, anhydrous dibasic calcium phosphate, and tribasic calcium

phosphate. Sugars include simple sugars, such as lactose, maltose, mannitol, fructose, sorbitol, saccharose, xylitol, isomaltose, and glucose, as well as complex sugars (polysaccharides), such as maltodextrin, amylodextrin, starches, and modified starches. The compositions may be formulated into various types of dosage forms, for instance as solutions or suspensions for parenteral or oral administration, as tablets or capsules for oral administration, ointments or lotions for transdermal administration etc. The above lists of excipients and forms are not exhaustive. The linezolid Form A prepared by the process of the present invention is useful as antibacterial agent, in treating various diseases caused by some types of bacteria, by

administering an effective amount thereof to a patient in need of such treatment. In particular, it is useful in the treatment of diabetic food infections caused by Gram-positive bacteria. Typically the effective amounts range from 1 mg to 500 mg, expressed as the amount of linezolid base, per day.

The invention will be further described with reference to the following non-limiting examples.

Example 1

Linezolid Form II (0.5 g) is dissolved in 20 ml of ethyl acetate at reflux. The hot solution is dropwise added, through a funnel preheated to 100°C, into 100 ml of n-heptane stirred at -10°C and containing 50 mg of linezolid Form A seeds. After 20 minutes of stirring at a temperature between -10 and 0° C, the suspension is filtered. The solid is washed with n-heptane and dried on air at room temperature. Yield : 0.32 g.

Example 2

Linezolid Form II (0.5 g) is dissolved in 20 ml of ethanol at reflux. The hot solution is dropwise added, through a funnel preheated to 100°C, into 100 ml of n-heptane stirred at -10°C and containing 50 mg of linezolid Form A seeds. After 10 minutes of stirring at a temperature between -10 and 0 °C, the suspension is filtered. The solid is washed with n-heptane and dried on air at room temperature. Yield : 0.50 g.

Example 3

Linezolid Form II (0.5 g) is dissolved in 20 ml of 2-propanol at reflux. The hot solution is dropwise added, through a funnel preheated to 100°C, into 50 ml of n-heptane stirred at -10°C and containing 50 mg of linezolid Form A seeds. After 10 minutes of stirring at a temperature between -10 and 0° C, the suspension is filtered. The solid is washed with n-heptane and dried on air at room temperature. Yield : 0.50 g.

The invention having been described it will be obvious that the same may be varied in many ways and all such modifications are contemplated as being within the scope of the invention as defined by the following claims.

Claims

Claims 1. A process for making a crystalline linezolid, comprising a step of dissolving linezolid in an organic solvent to obtain a solution followed by a step of adding the obtained solution into an antisolvent kept at a pre-selected temperature and seeded with crystals of the desired crystalline form of linezolid.
2. The process according to claim 1 , wherein the crystalline linezolid is the Form A of linezolid characterised by a XRPD powder diffraction pattern comprising the peaks at about 7.6,
9.6, 13.6, 14.9, 18.2, 18.9, 21.2, 22.3, 25.6, 26.9, 27.9 and 29.9 degrees 2 theta, when measured with CuKal radiation (λ = 1.54060 A).
3. The process according to claim 1-2, wherein the organic solvent is selected from an aliphatic alcohol, such as methanol, ethanol and isopropanol, a cyclic ether, such as 1 ,4-dioxane, and an aliphatic ester, such as ethyl acetate, and mixtures thereof.
4. The process according to claims 1-3, wherein the temperature of the solution is within the range from 50 °C up to the reflux temperature.
5. The process according to claims 1-4, wherein the concentration of the linezolid in the solution is within a range of between 10-100 ml of the solvent per 1 gram of linezolid.
6. The process according to claims 1-5 wherein the antisolvent is an aliphatic
hydrocarbon, preferably with 5 to 10 carbon atoms, and/or an aliphatic ether, preferably that of 4 to 10 carbon atoms.
7. The process according to claim 6, wherein the hydrocarbon is a hexane such as n- hexane, a heptane such as n-heptane, cyclohexane and/or petroleum ether, the aliphatic ether is methyl-/ert. -butyl ether; and mixtures thereof.
8. The process according to claims 1-7, wherein the pre-selected temperature of the antisolvent is within the range from -20°C to +25°C, preferably at a temperature lower than 0°C.
9. The process according to claims 1-8, wherein the mutual ratio between the antisolvent and the solvent is from 1 : 1 to 10 : 1 (v/v), advantageously from 2 : 1 to 7 : 1 (v/v) .
10. The process according to claims 1-9, wherein the antisolvent is seeded with crystals of the crystalline Form A of linezolid.
1 1. The process according to claims 1-10, wherein the relative amount of the seeds in respect to the weight of the linezolid in the solution is 1- 25 %.
12. The process according to claims 1-1 1 , wherein the crystallization provides a precipitate of the crystalline Form A of linezolid, which is essentially free from any other crystalline form of linezolid.
PCT/EP2009/007919 2009-10-28 2009-10-28 Process for making crystalline form a of linezolid WO2011050826A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/007919 WO2011050826A1 (en) 2009-10-28 2009-10-28 Process for making crystalline form a of linezolid

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2009/007919 WO2011050826A1 (en) 2009-10-28 2009-10-28 Process for making crystalline form a of linezolid
PCT/EP2010/001214 WO2011050865A1 (en) 2009-10-28 2010-02-23 Process for making crystalline form a of linezolid
PCT/EP2010/066348 WO2011051384A1 (en) 2009-10-28 2010-10-28 Process for making crystalline form a of linezolid
EP20100773295 EP2493867A1 (en) 2009-10-28 2010-10-28 Process for making crystalline form a of linezolid

Publications (1)

Publication Number Publication Date
WO2011050826A1 true true WO2011050826A1 (en) 2011-05-05

Family

ID=42048865

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2009/007919 WO2011050826A1 (en) 2009-10-28 2009-10-28 Process for making crystalline form a of linezolid
PCT/EP2010/001214 WO2011050865A1 (en) 2009-10-28 2010-02-23 Process for making crystalline form a of linezolid
PCT/EP2010/066348 WO2011051384A1 (en) 2009-10-28 2010-10-28 Process for making crystalline form a of linezolid

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/EP2010/001214 WO2011050865A1 (en) 2009-10-28 2010-02-23 Process for making crystalline form a of linezolid
PCT/EP2010/066348 WO2011051384A1 (en) 2009-10-28 2010-10-28 Process for making crystalline form a of linezolid

Country Status (1)

Country Link
WO (3) WO2011050826A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111048A1 (en) * 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
WO2015068121A1 (en) 2013-11-06 2015-05-14 Unimark Remedies Ltd. Process for preparation of crystalline form i of linezolid and its compositions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072923A1 (en) * 2011-09-19 2013-05-23 Cadila Healthcare Limited Process for the preparation of crystalline linezolid
CN102399200B (en) * 2011-12-14 2013-12-04 浙江新东港药业股份有限公司 Suspension crystallization method for preparing crystal form I of linezolid
WO2014101064A1 (en) * 2012-12-27 2014-07-03 上海创诺医药集团有限公司 Method for preparing linezolid crystalline form i
CN103893138B (en) * 2012-12-28 2017-09-29 成都国为生物医药有限公司 Containing linezolid Form tablets Ⅲ

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO2005035530A1 (en) * 2003-10-16 2005-04-21 Symed Labs Limited A novel crystalline form of linezolid
WO2006110155A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
US20070015753A1 (en) * 2005-07-15 2007-01-18 Glenmark Pharmaceuticals Limited Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
WO2009063505A2 (en) * 2007-10-08 2009-05-22 Usv Limited Process for preparation of (s) (n-[[3-[3-fluoro-4-(4-morpholinyl) hen l -2-oxo-5-oxazolidin l methyl]acetamide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
CA2572054A1 (en) 2004-06-29 2006-01-12 Teva Pharmaceutical Industries Ltd. Crystalline form iv of linezolid
WO2007026369A1 (en) 2005-08-29 2007-03-08 Symed Labs Limited A novel amorphous form of linezolid
DE502006002556D1 (en) 2005-09-06 2009-02-26 Ernst Schenkel Water-cooled grate element
WO2009140466A3 (en) * 2008-05-14 2010-03-04 Dr. Reddy's Laboratories Ltd. Linezolid co-crystals

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO2005035530A1 (en) * 2003-10-16 2005-04-21 Symed Labs Limited A novel crystalline form of linezolid
WO2006110155A1 (en) * 2004-06-29 2006-10-19 Teva Pharmaceutical Industries Ltd Solid forms of linezolid and processes for preparation thereof
US20070015753A1 (en) * 2005-07-15 2007-01-18 Glenmark Pharmaceuticals Limited Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
WO2009063505A2 (en) * 2007-10-08 2009-05-22 Usv Limited Process for preparation of (s) (n-[[3-[3-fluoro-4-(4-morpholinyl) hen l -2-oxo-5-oxazolidin l methyl]acetamide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013111048A1 (en) * 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2013120496A1 (en) 2012-02-14 2013-08-22 Pharmathen S.A. Process for the preparation of linezolid in crystalline form and salts thereof
WO2015068121A1 (en) 2013-11-06 2015-05-14 Unimark Remedies Ltd. Process for preparation of crystalline form i of linezolid and its compositions

Also Published As

Publication number Publication date Type
WO2011051384A1 (en) 2011-05-05 application
WO2011050865A1 (en) 2011-05-05 application

Similar Documents

Publication Publication Date Title
US20090247532A1 (en) Crystalline polymorph of sitagliptin phosphate and its preparation
US20060142283A1 (en) Crystalline form IV of linezolid
US20100010098A1 (en) Polymorphs of rasagiline hydrochloride
US7183272B2 (en) Crystal forms of oxcarbazepine and processes for their preparation
JPH11509865A (en) 5- (2- (4- (1,2-benzisothiazol-3-yl) -1-piperazinyl) ethyl) -6-chloro-1,3-dihydro -2 (1h) - indol-2-one ( = mesylate trihydrate of ziprasidone), their preparation and their use as dopamine d2 antagonists
EP1440969A1 (en) Alpha-form or beta-form crystal of acetanilide derivative
WO2007136510A2 (en) Polymorphic forms of imatinib mesylate and processes for their preparation as well as of amorphous imatinib mesylate and form alpha
US20090298947A1 (en) Polymorphic and amorphous forms of lacosamide and amorphous compositions
US20060111350A1 (en) Solid forms of linezolid and processes for preparation thereof
CN101891738A (en) Dasatinib polymorph and preparation method and medical composite thereof
US20100227839A1 (en) Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin- 5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US20070293702A1 (en) Novel crystalline forms of armodafinil and preparation thereof
WO2003082857A2 (en) Lansoprazole polymorphs and processes for preparation thereof
US20040063782A1 (en) Bicalutamide forms
WO2008077871A1 (en) Salts of tegaserod
WO2008099944A1 (en) Crystalline forms of thiazolidinedione derivative and its manufacturing method
WO2012020016A1 (en) Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
WO2012156951A1 (en) Polymorph of rifaximin and process for the preparation thereof
US20080090833A1 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha
WO2010151611A1 (en) Novel fumarate salts of a histamine h3 receptor antagonist
WO2004080961A2 (en) Crystalline and amorphous solids of pantoprazole and processes for their preparation
CN102086195A (en) Dasatinib polymorphic substance as well as preparation method and medicinal composition thereof
US20020107275A1 (en) Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
CN102336801A (en) Abiraterone acetate polymorphic substance and pharmaceutical composition
WO2013044816A1 (en) Crystalline forms of azilsartan and preparation and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09748716

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09748716

Country of ref document: EP

Kind code of ref document: A1